A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes

Mike Baxter; Yukiko Morimoto; Masami Tamiwa; Masakatsu Hattori; Xuejun Victor Peng; Robert Lubwama; Hiroshi Maegawa

doi:10.1007/s13300-020-00836-8

A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes

Diabetes Therapy ◽

10.1007/s13300-020-00836-8 ◽

2020 ◽

Vol 11 (7) ◽

pp. 1481-1496 ◽

Cited By ~ 1

Author(s):

Mike Baxter ◽

Yukiko Morimoto ◽

Masami Tamiwa ◽

Masakatsu Hattori ◽

Xuejun Victor Peng ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Observational Study ◽

Real World ◽

Basal Insulin ◽

Receptor Agonist ◽

Japanese Patients ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, singl

Journal of Diabetes Investigation ◽

10.1111/jdi.12694 ◽

2017 ◽

Vol 9 (2) ◽

pp. 332-340 ◽

Cited By ~ 25

Author(s):

Yutaka Seino ◽

Daisuke Yabe ◽

Takashi Sasaki ◽

Atsushi Fukatsu ◽

Hisae Imazeki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Fat Mass ◽

Receptor Agonist ◽

Japanese Patients ◽

Open Label ◽

Sodium Glucose Cotransporter ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study

Diabetes Therapy ◽

10.1007/s13300-020-00783-4 ◽

2020 ◽

Vol 11 (4) ◽

pp. 995-1005 ◽

Cited By ~ 2

Author(s):

Xuejun Victor Peng ◽

Rajeev Ayyagari ◽

Robert Lubwama ◽

Lizheng Shi ◽

Eboni G. Price-Haywood ◽

...

Keyword(s):

Type 2 Diabetes ◽

Observational Study ◽

Basal Insulin ◽

Retrospective Observational Study ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

The Lancet ◽

10.1016/s0140-6736(14)61335-0 ◽

2014 ◽

Vol 384 (9961) ◽

pp. 2228-2234 ◽

Cited By ~ 244

Author(s):

Conrad Eng ◽

Caroline K Kramer ◽

Bernard Zinman ◽

Ravi Retnakaran

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Combination Treatment ◽

Basal Insulin ◽

Receptor Agonist ◽

Meta Analysis ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence

Obesity Science & Practice ◽

10.1002/osp4.116 ◽

2017 ◽

Vol 3 (3) ◽

pp. 342-351 ◽

Cited By ~ 12

Author(s):

G. S. Carls ◽

R. Tan ◽

J. Y. Zhu ◽

E. Tuttle ◽

J. Yee ◽

...

Keyword(s):

Type 2 Diabetes ◽

Medication Adherence ◽

Real World ◽

Weight Change ◽

Receptor Agonist ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database

Diabetes Obesity and Metabolism ◽

10.1111/dom.13156 ◽

2017 ◽

Vol 20 (4) ◽

pp. 831-839 ◽

Cited By ~ 7

Author(s):

Liyue Tong ◽

Chunshen Pan ◽

Hongwei Wang ◽

Monica Bertolini ◽

Elisheva Lew ◽

...

Keyword(s):

Type 2 Diabetes ◽

Longitudinal Study ◽

Basal Insulin ◽

Receptor Agonist ◽

Administrative Claims ◽

Treatment Intensification ◽

Claims Database ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Real-World Comparative Effectiveness, Treatment Patterns, and Costs in Type 2 Diabetes Mellitus (T2DM) Patients Initiated on Canagliflozin 300 mg (CANA) or a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1)

Diabetes ◽

10.2337/db18-1287-p ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 1287-P

Author(s):

MUKUL SINGHAL ◽

HIANGKIAT (JASON) TAN ◽

CRAIG I. COLEMAN ◽

WILLIAM H. HERMAN ◽

JENNIFER CAI ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Real World ◽

Comparative Effectiveness ◽

Receptor Agonist ◽

Treatment Patterns ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study

Cardiovascular Diabetology ◽

10.1186/s12933-015-0178-3 ◽

2015 ◽

Vol 14 (1) ◽

pp. 10 ◽

Cited By ~ 38

Author(s):

Sanjoy K Paul ◽

Kerenaftali Klein ◽

David Maggs ◽

Jennie H Best

Keyword(s):

Type 2 Diabetes ◽

Observational Study ◽

Receptor Agonist ◽

Cardiovascular Outcomes ◽

Retrospective Observational Study ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study

Diabetology & Metabolic Syndrome ◽

10.1186/1758-5996-6-95 ◽

2014 ◽

Vol 6 (1) ◽

pp. 95 ◽

Cited By ~ 20

Author(s):

Kana Inoue ◽

Norikazu Maeda ◽

Yuya Fujishima ◽

Shiro Fukuda ◽

Hirofumi Nagao ◽

...

Keyword(s):

Type 2 Diabetes ◽

Body Weight ◽

Glycemic Control ◽

Observational Study ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Long Term Impact

Download Full-text

Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study

Journal of Diabetes Investigation ◽

10.1111/jdi.12749 ◽

2017 ◽

Vol 9 (3) ◽

pp. 558-566 ◽

Cited By ~ 1

Author(s):

Antonio Nino ◽

Inaha Okuda ◽

Timothy H Wilson ◽

Lynn Yue ◽

Hiromu Nakajima ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Japanese Patients ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509–2518

Diabetes Care ◽

10.2337/dci21-0004 ◽

2021 ◽

Vol 44 (11) ◽

pp. e196-e197

Author(s):

Julio Rosenstock

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Insulin Therapy ◽

Randomized Trial ◽

Diabetes Care ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Insulin Use

Download Full-text